Baili Tianheng announced that the company's self-developed phase III randomized controlled clinical trial for her2-expressed platinum-resistant platinum-resistant ovarian cancer, fallopian tube cancer, and primary peritoneal cancer was recently completed.

Zhitongcaijing · 2d ago
Baili Tianheng announced that the company's self-developed phase III randomized controlled clinical trial for her2-expressed platinum-resistant platinum-resistant ovarian cancer, fallopian tube cancer, and primary peritoneal cancer was recently completed.